CT55 and chronic myelogenous leukemia, BCR-ABL1 positive: Here, we demonstrated the potential role of T-cell immunity against CXorf48 antigen in CML patients who achieved TFR and suggested this antigen could be a valuable therapeutic target in CML patients.